COVID-19
Not recruitingSafety and Immunogenicity of SARS-COV-2 VIRUS, VARIANT LP.8.1, SPIKE PROTEIN, RECEPTOR BINDING DOMAIN FUSION HOMODIMER Vaccine in Adults with COVID-19
Safety and Immunogenicity of SARS-COV-2 VIRUS, VARIANT LP.8.1, SPIKE PROTEIN, RECEPTOR BINDING DOMAIN FUSION HOMODIMER Vaccine in Adults with COVID-19
- Disease:COVID-19
- Substances:SARS-COV-2 VIRUS, VARIANT LP.8.1, SPIKE PROTEIN, RECEPTOR BINDING DOMAIN FUSION HOMODIMER
Spain- Participants:18–64 years · 65+ years · Healthy volunteers
- Substances:SARS-COV-2 VIRUS, VARIANT LP.8.1, SPIKE PROTEIN, RECEPTOR BINDING DOMAIN FUSION HOMODIMER
- Sponsor:Hipra Scientific S.L.








